newsfilter
← Latest News
GlobeNewswire·

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

  • Tvardi Therapeutics (NASDAQ: TVRD) will participate in one-on-one investor meetings at the Raymond James Biotech Innovation Symposium in New York City on April 14, 2026.
  • The company is a clinical-stage biopharmaceutical focused on developing oral small molecule therapies targeting STAT3 for inflammatory & proliferative diseases.
  • Tvardi is conducting clinical trials for TTI-101 in hepatocellular carcinoma (NCT05440708) & TTI-109 in healthy volunteers.
  • STAT3 serves as a central mediator in signaling pathways driving uncontrolled proliferation, survival, immune dysregulation, & cancer cell immune evasion.
  • Investor inquiries can be directed to Tvardi Investor Relations at ir@tvardi.com or to PJ Kelleher of LifeSci Advisors at pkelleher@lifesciadvisors.com.